Genetic testing has shown promising results to inform and target therapy in cancer; however, uptake is suboptimal due to racial, ethnic, and socioeconomic barriers. Clinicians practicing in the community oncology setting often play the role of genetic counselor to patients with cancer and need support to improve access to necessary, high-quality genetic services for patients of all backgrounds. To achieve this and to facilitate improved patient outcomes, clinicians need to proactively improve awareness and education on genetic counseling.
In the second installment of this CME Outfitters Snack series, expert faculty will discuss strategies for providing high-quality genetic counseling and services for underserved patients with cancer, including leveraging health technology (e.g. telehealth), utilizing a collaborative/interprofessional approach to genetic counseling, and implementing a workable process for patient identification and triage.
Upon completion of this activity, learners will be able to better employ strategies to provide genetic counseling for patients with cancer.
Supported by an educational grant from Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses and pharmacists specializing in pathology, oncology or surgical oncology caring for patients with cancer in community settings.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Arun reports the following financial relationships:
Grants: Department of Defense (DOD); Cancer Prevention & Research Institute of Texas (CPRIT); National Cancer Institute (NCI); and Susan G. Komen
Research Support: AstraZeneca (paid to the institution)
Dr. Ioffe reports the following financial relationships:
Advisory Board: Immunogen/GOG Foundation and Seagen
Consultant: Targeted Oncology and OncLive
Research Support: 2021: Pilot study of organoid model of uterine and ovarian carcinosarcomas. Principal investigator, Granted by Research Committee, Department of Gynecology and Obstetrics (Loma Linda University)
2022-2023/4: Grant to promote collaborative and translational research (GCAT). Principal investigator (10% time), Reversing Chemoresistance in Recurrent Ovarian Cancer (Loma Linda University)
Speakers Bureau: OncLive Panel
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).